

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Roddi J. SIMPSON et al.

Serial No. 10/657,171

Art Unit: 3763

Filed: September 9, 2003

Examiner: Han, Mark K.

For: FIXED NEEDLE SYRINGE
WITH PROTECTIVE
HOUSING

Atty Docket: 0100/0162

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
FILED PURSUANT TO 37 CFR 1.97

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

For insuring compliance with the applicants' duty of disclosure under 37 CFR §1.56, the undersigned hereby submits the attached Form PTO-1449 listing a reference for consideration by the Examiner in charge of the above-identified patent application.

The attached Terumo publication is not believed to be prior art to the instant invention inasmuch as it was published after the filing date of the instant application.

These documents are being submitted:

- ☐ within three months of the filing of the above U.S. national application or of the date of entry of the U.S. national stage in an International Patent Application (no fee is due); (37 CFR §1.97(b))
- ☒ before receiving a first Office Action on the merits of the above-identified patent application (no fee is due); (37 CFR §1.97(b))

☐ following receipt of a first Office Action, but before issuance of a Final Office Action or a Notice of Allowance (if this box is checked, one of the last three boxes also must be checked); (37 CFR §1.97(c))

☐ concurrently with the filing of the RCE (37 CFR 1.114)

OR

☐ following receipt of a Notice of Allowance or a Final Office Action. The undersigned hereby requests consideration of this Information Disclosure Statement after the mailing the Final Office Action or Notice of Allowance by filing this Information Disclosure Statement under 37 CFR §1.97(d)

☐ The Commissioner is authorized to debit \$180.00 for payment of the fee set forth in 37 CFR § 1.17(p). (37 CFR §1.97(d)(2))

☐ The undersigned certifies that each item of this information is being submitted within three months of the date it was cited European Patent Office in a counterpart application. (37 CFR §1.97(e)(1))

☐ The undersigned certifies that, after making reasonable inquiry, he/she has no knowledge that any item of this information was cited by a foreign patent office in a counterpart application or was known more than three months prior to this submission. (37 CFR §1.97(e)(2))

The Commissioner is hereby authorized to charge payment of any deficiency in the above fee(s) or to charge any additional fees required under 37 CFR § 1.16 or 1.17 or credit any overpayment to Deposit Account No. 50-0501. A duplicate copy of this authorization is attached for the Finance Branch.

Respectfully submitted,




Louis Woo, Reg. No. 31,730
Law Offices of Louis Woo
717 North Fayette Street
Alexandria, Virginia 22314
Phone: (703) 299-4090

Date: May 23, 2005

FORM PTO-1449

INFORMATION DISCLOSURE CITATION

Atty Docket
0100/0162Serial No.
10/657,171Applicant
Roddi James Simpson et al.Filing Date
September 9, 2003Group Art Unit
3763

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Sub-Class	Filing Date
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Sub-Class	Translation
	AL						
	AM						
	AN						
	AO						
	AP						

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR		Terumo SurGuard Safety Insulin Syringe, Terumo Medical Corporation, Jan. 2005
	AS		
	AT		

Examiner

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP § 609.
 Draw line through citation if not in conformance and not considered.
 Include copy of this form with next communication to Applicant.